PACB - Pacific Biosciences of California, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Menlo Park,
United States
Type: Equity
PACB price evolution
PACB
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $99.87 | $76.95 | $180.21 | |
| Short term investments | $410.28 | $485.27 | $451.5 | |
| Net receivables | $29.38 | $32.43 | $30.32 | $36.62 |
| Inventory | $65.74 | $68.59 | $67.34 | $56.68 |
| Total current assets | $584.23 | $628.14 | $677.02 | $742.05 |
| Long term investments | $1.92 | $2.42 | $2.42 | |
| Property, plant & equipment | $49.3 | $57.3 | $67.96 | $69.03 |
| Goodwill & intangible assets | $812.34 | $912.39 | $919.25 | |
| Total noncurrent assets | $881.35 | $992.9 | $1003.97 | |
| Total investments | $412.2 | $487.69 | $453.93 | |
| Total assets | $1450.05 | $1509.49 | $1669.92 | $1746.01 |
| Current liabilities | ||||
| Accounts payable | $12.06 | $17.49 | $21.01 | $15.06 |
| Deferred revenue | $24.92 | $23.47 | $21.87 | |
| Short long term debt | $12.49 | $9.77 | $9.59 | |
| Total current liabilities | $60 | $78.39 | $72.95 | $95.03 |
| Long term debt | $893.14 | $912.46 | $921.59 | $923.85 |
| Total noncurrent liabilities | $938.4 | $947.95 | $949.68 | |
| Total debt | $924.95 | $931.37 | $933.44 | |
| Total liabilities | $996.93 | $1016.79 | $1020.9 | $1044.71 |
| Shareholders' equity | ||||
| Retained earnings | -$2151.3 | -$2090.57 | -$1917.25 | -$1839.08 |
| Other shareholder equity | $1.55 | -$0.52 | -$0.31 | $0.22 |
| Total shareholder equity | $492.7 | $649.02 | $701.3 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $180.21 | $325.39 | $461.23 | $82.45 |
| Short term investments | $451.5 | $447.23 | $583.67 | $237.2 |
| Net receivables | $36.62 | $18.79 | $24.24 | $16.84 |
| Inventory | $56.68 | $50.38 | $24.6 | $14.23 |
| Total current assets | $742.05 | $852.07 | $1101.13 | $355.59 |
| Long term investments | $2.42 | $2.92 | $4.59 | $3.5 |
| Property, plant & equipment | $69.03 | $81.34 | $79.12 | $54.85 |
| Goodwill & intangible assets | $919.25 | $820.22 | $820.95 | |
| Total noncurrent assets | $1003.97 | $915.01 | $905.84 | $58.39 |
| Total investments | $453.93 | $450.15 | $588.27 | $240.7 |
| Total assets | $1746.01 | $1767.09 | $2006.97 | $413.98 |
| Current liabilities | ||||
| Accounts payable | $15.06 | $12.03 | $11 | $3.58 |
| Deferred revenue | $21.87 | $32.29 | $36.03 | $10.29 |
| Short long term debt | $9.59 | $8.89 | $7.71 | $4.33 |
| Total current liabilities | $95.03 | $263.33 | $71.71 | $38.5 |
| Long term debt | $923.85 | $896.68 | $946.04 | $37.67 |
| Total noncurrent liabilities | $949.68 | $940.85 | $1144.27 | $39.99 |
| Total debt | $933.44 | $946.64 | $953.75 | $42 |
| Total liabilities | $1044.71 | $1204.18 | $1215.98 | $78.49 |
| Shareholders' equity | ||||
| Retained earnings | -$1839.08 | -$1532.34 | -$1218.09 | -$1036.87 |
| Other shareholder equity | $0.22 | -$4.76 | -$1.09 | $0.09 |
| Total shareholder equity | $701.3 | $562.9 | $790.99 | $335.49 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $36.01 | $38.81 | $58.36 | |
| Cost of revenue | $30.07 | $27.53 | $48.79 | |
| Gross Profit | $5.94 | $11.28 | $9.57 | |
| Operating activities | ||||
| Research & development | $38.48 | $43.45 | $44.54 | |
| Selling, general & administrative | $45.88 | $43.75 | $46 | |
| Total operating expenses | $181.78 | $92.71 | $96.02 | |
| Operating income | -$175.85 | -$81.43 | -$86.45 | |
| Income from continuing operations | ||||
| EBIT | -$169.78 | -$74.6 | -$79.17 | |
| Income tax expense | -$0.72 | |||
| Interest expense | $3.54 | $3.58 | $3.57 | |
| Net income | ||||
| Net income | -$173.32 | -$78.18 | -$82.02 | |
| Income (for common shares) | -$173.32 | -$78.18 | -$82.02 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $200.52 | $128.3 | $130.51 | $78.89 |
| Cost of revenue | $147.74 | $79.27 | $71.65 | $46.33 |
| Gross Profit | $52.78 | $49.03 | $58.86 | $32.57 |
| Operating activities | ||||
| Research & development | $187.17 | $193 | $112.9 | $64.15 |
| Selling, general & administrative | $169.82 | $160.85 | $124.12 | $72.8 |
| Total operating expenses | $372.19 | $353.85 | $268.15 | $136.95 |
| Operating income | -$319.41 | -$304.82 | -$209.29 | -$104.39 |
| Income from continuing operations | ||||
| EBIT | -$303.82 | -$299.56 | -$262.34 | $29.67 |
| Income tax expense | -$11.42 | -$93.65 | ||
| Interest expense | $14.34 | $14.69 | $12.53 | $0.27 |
| Net income | ||||
| Net income | -$306.74 | -$314.25 | -$181.22 | $29.4 |
| Income (for common shares) | -$306.74 | -$314.25 | -$181.22 | $29.4 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$173.32 | -$78.18 | -$82.02 | |
| Operating activities | ||||
| Depreciation | $14.29 | $12.01 | $11.7 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $17.22 | $19.52 | $16.58 | |
| Total cash flows from operations | -$54.26 | -$75.68 | -$57.56 | |
| Investing activities | ||||
| Capital expenditures | -$1.48 | -$3.88 | -$2.02 | |
| Investments | $78.32 | -$30.26 | -$64.55 | |
| Total cash flows from investing | $65.77 | $76.84 | -$34.14 | -$66.58 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.89 | $0.94 | ||
| Net borrowings | -$0.15 | -$0.34 | -$0.49 | |
| Total cash flows from financing | $7.21 | -$0.15 | $6.55 | -$81.6 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$102.43 | $22.42 | -$103.27 | -$205.74 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$306.74 | -$314.25 | -$181.22 | $29.4 |
| Operating activities | ||||
| Depreciation | $26.53 | $17.32 | $11.59 | $9.3 |
| Business acquisitions & disposals | -$0.1 | -$319.79 | ||
| Stock-based compensation | $72.12 | $78.61 | $73.36 | $17.53 |
| Total cash flows from operations | -$259.17 | -$263.21 | -$111.18 | $19.5 |
| Investing activities | ||||
| Capital expenditures | -$8.84 | -$16.75 | -$5.93 | -$1.04 |
| Investments | $13.55 | $133.01 | -$352.81 | -$218.28 |
| Total cash flows from investing | $4.6 | $116.08 | -$678.53 | -$219.32 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $204.52 | $11.23 | $326.65 | $233.84 |
| Net borrowings | -$9.22 | -$1.61 | $895.17 | -$16 |
| Total cash flows from financing | $108.89 | $9.62 | $1169.58 | $251.84 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$145.68 | -$137.51 | $379.87 | $52.02 |
News
Fundamentals
| Market cap | $539.41M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 273.81M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.49 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 9.74 |
| Quick ratio | 8.64 |